Construction and humanization of a functional bispecific EGFR × - CD16 diabody using a refolding system

Ryutaro Asano, Makoto Nakayama, Hiroko Kawaguchi, Tsuguo Kubota, Takeshi Nakanishi, Mitsuo Umetsu, Hiroki Hayashi, Yu Katayose, Michiaki Unno, Toshio Kudo, Izumi Kumagai

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


We previously reported the construction and activity of a humanized, bispecific diabody (hEx3) that recruited T cells towards an epidermal growth factor receptor (EGFR) positive tumor. Herein, we describe the construction of a second functional, fully humanized, anti-EGFR bispecific diabody that recruits another subset of lymphocyte effectors, the natural killer cells, to EGFR-expressing tumor cells. After we confirmed that an anti-EGFR × anti-CD16 bispecific diabody (Ex16) consisting of a previously humanized anti-EGFR variable fragment (Fv) and a mouse anti-CD16 Fv had growth inhibitory activity, we designed a humanized anti-CD16 Fv to construct the fully humanized Ex16 (hEx16). However, the humanized form had lower activity for inhibition of cancer growth. To restore its growth inhibitory activity, we introduced mutations into the Vernier zone, which is located near the complementarity- determining regions and is involved in their binding activity. We efficiently prepared 15 different hEx16 mutants by expressing each chimeric single-chain component for hEx16 separately. We then used our in vitro refolding system to select the most functional mutant, which had a growth inhibitory effect comparable with that of the commercially available chimeric anti-EGFR antibody, cetuximab. Our refolding system could aid in the efficient optimization of other proteins with heterodimeric structure. To restore growth inhibitory activity of a humanized bispecific EGFR × CD16 diabody (hEx16), we efficiently prepared 15 different hEx16 mutants by using a proven in vitro refolding method. Some mutants showed a recovery of binding strength to over 10 times the original strength of hEx16 and the cancer cell growth inhibition was also restored for several mutants.

Original languageEnglish
Pages (from-to)223-233
Number of pages11
JournalFEBS Journal
Issue number2
Publication statusPublished - 2012 Jan


  • CD16
  • bispecific diabody
  • cancer immunotherapy
  • epidermal growth factor receptor
  • humanization

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Construction and humanization of a functional bispecific EGFR × - CD16 diabody using a refolding system'. Together they form a unique fingerprint.

Cite this